Recent research published in The Lancet medical journal revealed to date more than three-quarters of the hospitalized population suffers from at least one symptom of Coronavirus infection after six months of recovery. Regardless of continual care, the long-term presence of the symptoms of COVID 19 was inevitable.
Senior author Bin Cao, of the National Center for Respiratory Medicine, reported, “as the disease is new, the long terms effects are yet to be known. For example, fatigue or muscle weakness along with sleep disturbance were the most common symptoms experienced by previous patients.”
He further added that patients with severe infections were kept under ongoing care and followed up to observe any long term effects to prevent the descent of their health.
On the other hand, the World Health Organization (WHO) identified that the virus did not only impose a risk for the hospitalized patient but also targeted the young healthy population.
The study in Jinyintan Hospital in Wuhan registered approximately 1,733 COVID-19 patients between January and May last year. The average aged patients about 57 years, were placed under constant observation to evaluate the disease impact on their quality of life. On further investigation, it was deduced that 76 percent of patients in the follow-up (1,265 of 1,655) presented with symptoms; 63 percent faced muscle weakness or fatigue whereas 26 percent suffered from sleep disturbance.
Moreover, the physicians re-evaluated the blood antibody of 94 subjects to determine the risk for reinfection whose antibody level dropped by 52.5% than previous records. A similar study by Norberto Perico and Giuseppe Remuzzi, from Italy’s Istituto di Ricerche Farmacologiche Mario Negri IRCCS,divulged concerns for the deterioration effect of the pandemic. Hence, they recommended, “ conduct prospective multidisciplinary research in the United States and Britain to gain deeper insights into therapies to mitigate the long-term consequences of COVID-19 on multiple organs and tissues.”